In our previous study, we proposed that the pre-LVAD plasma level of endostatin can be a good biomarker to predict renal function improvement, while the postoperative 1-week plasma level of cystatin C can help early identify high-risk AKI patients in the first month after LVAD implantation [4]. This evidence concerns the gene COL18A1 and acute kidney injury.